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Abstract
Background: We describe molecular processes that can facilitate pathogenesis of Alzheimer’s disease (AD) by analyzing the
catalytic cycle of a membrane-imbedded protease c-secretase, from the initial interaction with its C99 substrate to the final
release of toxic Ab peptides.
Results: The C-terminal AICD fragment is cleaved first in a pre-steady-state burst. The lowest Ab42/Ab40 ratio is observed in
pre-steady-state when Ab40 is the dominant product. Ab42 is produced after Ab40, and therefore Ab42 is not a precursor
for Ab40. The longer more hydrophobic Ab products gradually accumulate with multiple catalytic turnovers as a result of
interrupted catalytic cycles. Saturation of c-secretase with its C99 substrate leads to 30% decrease in Ab40 with concomitant
increase in the longer Ab products and Ab42/Ab40 ratio. To different degree the same changes in Ab products can be
observed with two mutations that lead to an early onset of AD, DE9 and G384A. Four different lines of evidence show that c-
secretase can bind and cleave multiple substrate molecules in one catalytic turnover. Consequently depending on its
concentration, NotchDE substrate can activate or inhibit c-secretase activity on C99 substrate. Multiple C99 molecules
bound to c-secretase can affect processive cleavages of the nascent Ab catalytic intermediates and facilitate their premature
release as the toxic membrane-imbedded Ab-bundles.
Conclusions: Gradual saturation of c-secretase with its substrate can be the pathogenic process in different alleged causes
of AD. Thus, competitive inhibitors of c-secretase offer the best chance for a successful therapy, while the noncompetitive
inhibitors could even facilitate development of the disease by inducing enzyme saturation at otherwise sub-saturating
substrate. Membrane-imbedded Ab-bundles generated by c-secretase could be neurotoxic and thus crucial for our
understanding of the amyloid hypothesis and AD pathogenesis.
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Introduction
Alzheimer’s disease is a slowly progressing neurodegenerative
disorder characterized by steadily advancing dementia that is
often coupled with insidious onsets of agnosia, aphasia, and
apraxia [1]. The current therapy is only symptomatic, and there
is no an effective cure or a preventive treatment available [1]. A
large body of basic and pharmaceutical research dedicated to
tackle the problem of Alzheimer’s disease is providing a steadily
growing number of potential targets [2], and some very potent
drug candidates [3,4]. Changes in cholesterol metabolism [5], G-
protein coupled receptors [6], Ab clearance [5,7,8], mitochon-
drial dysfunction [9], or changes in APP metabolism [8] are part
of a growing list of cellular processes that have been implicated in
the pathogenesis. Different alleged causes of Alzheimer’s disease
have one focal point, a membrane imbedded protease c-
secretase, the key enzyme for production of toxic amyloid-b
(Ab) peptides [10].
Studies of catalytic mechanism of c-secretase have presented
some unique biochemical and biophysical question and experi-
mental challenges [3,11,12]. After complex posttranslational
processing, the active enzyme is imbedded in cell membranes
and composed of four loosely connected proteins: Aph1, Pen2,
glycosylated nicastrin, and endo-proteolyzed presenilin as the
catalytic core [13]. c-Secretase is an aspartic protease [3,14], with
unique preference for some mechanism-based inhibitors [15],
unique sequence motifs in the active site [11,16], and the optimal
pH close to the physiological pH [17]. The active site aspartates
are located in the central aqueous cavity [18], that can be observed
using electron microscopy [19]. The central aqueous cavity is also
observed in much smaller intramembrane proteases that have
known crystal structures and it could be a result of functionally
convergent evolution [11].
Genetics [20], cell biology [2,10,12], and drug development
studies [21] have indicated that specific changes in enzymatic
mechanism of c-secretase can be enough to trigger development of
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can affect more than one third of all amino acids in presenilin 1
(currently about 165 amino acids are listed at www.molgen.ua.ac.
be/ADMutations). Different FAD mutations lead to onset of the
disease at different age [20], indicating that there are variations in
the enzymatic mechanism that make some mutants more prone to
the disease than the others. It is unknown how many different
enzymatic mechanisms FAD mutations represent, nor whether
there is a common enzymatic feature that is shared by the WT and
FAD mutants and leads to the development of disease. Apart from
FAD mutations, unknown differences in the enzymatic mechanism
make Aph1A subunit of c-secretase more likely to support the
pathogenesis than Aph1B subunit [22]. Increase in extent of c-
secretase saturation with its substrate can be a risk factor for
development of the disease [23–36], possibly due to specific
changes in the enzymatic mechanism [37,38]. Phase III clinical
trials showed that c-secretase inhibitor semagacestat can accelerate
the cognitive decline in patients [21]. This serious setback could be
a result of the complex inhibition mechanism that shows some
features that could facilitate development of the disease [39–41].
c-Secretase has probably more than 50 different substrates, the
only substrate linked to Alzheimer’s disease is C99, the 99 amino-
acid-long C-terminal domain of Amyloid Precursor Protein, APP
(APP-C99 [10]). About 25 FAD mutations leading to the disease
are found in the C99 sequence (www.molgen.ua.ac.be/
ADMutations). The molecular mechanism that makes those
mutations pathogenic is unknown. Some FAD mutations are
known to affect C99 dimerization [42–47]. C99 dimerization
correlates with the molecular events associated with the disease,
but the actual mechanism is not yet adequately described [42–47].
NMR studies showed that C99 substrate is a transmembrane helix
[42], with relatively unstructured hydrophilic arms at the C-
terminus and the N-terminus. A series of ingenious studies by
Ihara and colleagues gave a number of independent lines of
evidence that showed that c-secretase can cleave C99 at multiple
sites [37,40,48–50]. The C-terminal domain is cleaved-off first just
underneath the membrane surface. The result is a hydrophobic
Ab fragment and a hydrophilic AICD fragment (Amyloid Intra
Cellular Domain). The hydrophobic Ab fragment is subsequently
processively cleaved in steps of three amino acids, to give
fragments varying in length from 37 to 49 amino acids [37,50].
The cleavage sites appear to be interconnected [40,48,49], AICD
fragment 50–99 will give Ab fragments 1–49, 1–46, 1–43, 1–40
and 1–37, while AICD fragment 49–99 will give Ab fragments 1–
48, 1–45, 1–42, and 1–38.
A predominant fraction of FAD mutations in C99 substrate is
located within Ab sequence [42]. The disease is often attributed to
an increase in Ab42/Ab40 ratio that could be a result of ‘‘a gain of
function for production of Ab 1–42’’, or ‘‘a loss of function for
production of Ab 1–40’’ [20]. Recent studies increasingly show
that such debate is an oversimplification [46,51]. The large
amyloid plaques can not be clearly correlated with the
pathogenesis [51], so the current research focus is shifted to fibril
precursors, most notably unstable oligomers of Ab peptides
[51–53]. The oligomerization of Ab peptides is not an amorphous
hydrophobic aggregation [51,52,54,55]. The oligomerization is
driven by specific structural forces that have preferred Ab 1–40/
Ab 1–42 ratio [56]. The oligomer toxicity depends on number of
Ab peptides in the oligomer [53]. Individual Ab peptides have a
highly dynamic structure, varying from a-helix to random-coil to
b-sheet [51–55,57]. Such structural fluctuations appear to be
crucial for the formation of oligomeric structures and their
toxicity [51–54,57,58]. Furthermore, Ab 1–43 can be more toxic
than Ab 1–42 in cells and in experimental animals [59], while
some cell surface proteins can enhance toxicity of Ab peptides
[60]. Studies of enzymatic mechanism of c-secretase can greatly
advance our ability to understand the toxicity of different Ab
peptides [59,61].
Surprisingly, very little effort has been invested in attempts to
integrate the results from different studies of c-secretase, its C99
substrate, and its Ab products into one coherent molecular
mechanism. In presented studies we use some standard approach-
es for studies of enzyme mechanism [62] to analyze WT and two
FAD mutations in presenilin 1 of c-secretase. We trace C99
cleavages from the initial c-secretase-C99-interaction, to the final
release of Ab product (oligomers). The current knowledge about c-
secretase, its C99 substrate, and its Ab products is integrated in
one coherent molecular mechanism in an attempt to describe
pathogenesis of Alzheimer’s disease and to propose novel strategies
for development of the drug candidates.
Results
Catalytic products of c-secretase can be separated in
time
Pre-steady state phase of an enzymatic reaction is routinely used
for mapping the order of catalytic steps [62]. Pre-steady state of c-
secretase reaction can be observed by capturing the earliest stage
of the first catalytic turnover [62,63], when AICD, Ab 1–40 and
Ab 1–42 products initially appear in time (Fig. 1 and Table 1). We
find that the C-terminal AICD fragment is produced prior to Ab
1–40 and Ab 1–42 fragments in a pre-steady-state burst (Fig. 1 A).
The pre-steady-state burst in AICD production indicates that the
initial AICD cleavage is fast, and the steady-state rate-limiting step
is production and release of different Ab products (as illustrated in
detail in Fig. S1). Y-axis intercept of a pre-steady-state burst can be
used to estimate initial concentration of an enzyme-substrate
complex (p.p. 156–158 and p. 238 in ref. [62]). The Y-axis
intercept for pre-steady-state burst in AICD production indicates
that the initial concentration of c-secretase-C99-complex can be in
the range between 5 to 10 nM (Table 1). These values are about 5
to 10 times higher than the values we can measure using the
enzyme titration with a highly potent inhibitor LY-411,575 (Fig.
S2). As a general principle, the product generated in a pre-steady
state burst can be several times higher than the initial
concentration of the enzyme-substrate complex if the enzyme
can process multiple substrate molecules in one catalytic turnover
[62,64] (i.e. one catalytic turnover consists of multiple catalytic
cycles). Thus, we propose that the high burst magnitude is the first
out of several lines of evidence that indicates that c-secretase can
bind and cleave multiple C99 molecules in one catalytic turnover.
The time profiles for Ab 1–40 and Ab 1–42 production show an
initial lag (Fig. 1 A–B). The initial lag for Ab 1–42 is clearly longer
than the lag for Ab 1–40 (Table 1). This indicates that Ab 1–40 is
produced prior to Ab 1–42, so that Ab 1–42 cannot be a precursor
for Ab 1–40. About a dozen of different situations can lead to an
early lag in enzyme activity [63]. About a half of them are due to
the method of detection, the other half to specific features in the
enzymatic mechanism. Duration of the lag for Ab 1–40 and Ab 1–
42 correlates with the extent of enzyme saturation with its C99
substrate, and traces of the initial lag can be detected in earlier
publications that used a different experimental set-up [49,65,66].
Calibration of the AlphaScreenH method using synthetic Ab 1–40
and Ab 1–42 peptides shows that this method has a linear response
well beyond the range measured in the lag. Therefore, the lag is a
result of enzymatic mechanism rather than an artifact caused by
the measurements. The lag can represent the time period that c-
secretase needs to process the stepwise cleavages of Ab catalytic
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S1). The difference in the length of initial lag (Fig. 1) shows that
changes in the enzymatic mechanism that correspond to a shift
from Ab 1–40 to Ab 1–42 production roughly coincide with the
reaction progress from the first to the second turnover (Fig. 1 C).
The lowest Ab42/Ab40 ratio is observed very early in the lag, i.e.
in the early pre-steady-state of the first catalytic turnover (Fig. 1C).
We further analyzed the early stage of the reaction using urea
gels (Fig. 2 A–B) that can separate Ab 1–40 and Ab 1–42 from the
other Ab 1-x products (the urea gels are not as sensitive as the
AlphaScreenH measurements). Similar to the AlphaScreenH results
(Fig. 1), the urea gels show that Ab 1–40 dominates the earliest
stage of the reaction and that Ab 1–42 production starts after Ab
1–40 (Fig. 2 A). The longer more hydrophobic Ab products are
below detection limits in the earliest stage of reaction, and then
gradually accumulate with the reaction progress in time.
Ultimately, at the late stage of the reaction the longer Ab products
become comparable to Ab 1–40 and Ab 1–42 (Fig. 2B). Thus, the
longer more hydrophobic Ab products observed in the late stage of
the reaction are not transient catalytic intermediates, but products
of an incomplete sequence of the processive cleavages (Fig. S1).
This shift to the longer Ab products can explain the observed drop
in Ab 1–40 and Ab 1–42 production at the late stage of reaction
(Fig. 1). In summary, we conclude that the reaction progress in
time can affect the enzyme’s ability to process the longer more
hydrophobic Ab peptides to Ab 1–40 and Ab 1–42 (different
examples of factors that control processing and accumulation of
reaction intermediates are illustrated in more details in Fig. S1 and
on p.145 in ref. [62]).
Changes in c-secretase activity upon saturation with its
C99 substrate, small molecule inhibitor DAPT, or
NotchDE substrate
Previous studies on humans, experimental animals, cells, and
enzymes indicated that increase in the extent of c-secretase
saturation with its C99 substrate can lead to molecular processes
that can support the pathogenesis [23–35,37,38]. We analyze how
catalytic mechanism of c-secretase can be affected by saturation
with its C99 substrate (Fig. 3, 4, 5), or small molecule inhibitor
DAPT (Fig. 3), or its other substrate NotchDE (Fig. 6).
We find that different products of c-secretase reach saturation at
different concentrations of C99 substrate (Fig. 3 and Table 2).
Michaelis-Menten constant (Km) for Ab 1–40 is lower than the
constants for AICD or Ab 1–42 (Table 2). The mechanistic
significance of these differences can be revealed by dividing the
data points for Ab 1–40 and Ab 1–42 with the best-fit Michaelis–
Menten curve for total AICD (i.e. the corresponding data points
for total AICD) (Fig. 4A and Fig. S3). Such analysis is justified by
the fact that every Ab product has to have one complementary
AICD product [37]. We find that at the lowest saturation about
65% of all AICD fragments produced will have one complemen-
tary Ab 1–40, while approximately 30% will have one comple-
mentary Ab 1–42 (Fig. 4A). Intriguingly, with increasing substrate
concentrations the relative amount of Ab 1–40 and Ab 1–42
product gradually decreased, and the effect is predominately seen
on Ab 1–40 (this is visualized by the steeper descent of the Ab 1–
40/ total-AICD ratio compared to the Ab 1–42/ total-AICD ratio
(Fig. 4A and Fig. S3)). In total, Ab 1–40/AICD shows about 30%
decrease, while Ab 1–42/AICD shows about 6% decrease at the
maximal substrate concentration. Consequently, an increase in
Figure 1. Different phases in c-secretase reaction can be separated in time. The reactions were prepared using CHAPSO enriched c-
secretase membranes (total protein 0.25 mg/ml) and saturating concentration of C99 substrate (3.0 mM). (A–B). Early time points and the pre-steady-
state [62] for AICD, Ab 1–40 and Ab 1–42 production (panel B is zoom-in on panel A). The best-fit profile for AICD production was calculated using the
equation for pre-steady-state burst (eqn. 1, Table 1), while the best-fit profiles for Ab 1–40 and Ab 1–42 production were calculated using the
equation for enzyme hysteresis (eqn. 2, Table 1). (C) The time profiles Ab 1–40 and Ab 1–42 from figure 1 were used to calculate the changes in Ab42/
Ab40 ratio as a function of the reaction time (Ab42/Ab40 ratio is shown, rather than Ab40/Ab42 ratio, in an attempt to follow standards in the
literature).
doi:10.1371/journal.pone.0032293.g001
Table 1. Kinetic parameters for pre-steady state burst and
initial lags (Fig. 1)
a, c.
AICD
a Ab 1–40
c Ab 1–42
c
Intercept nM
a 8.262 Lag-transition/h
c 662.4 260.6
2sCI
b [6,13] 2sCI
b [3.1, 12] [1,3]
Pre-steady rate/h
a 1.260.4 Steady-state nM/h 1561.7 660.9
2sCI
b [1.06, 1.75] 2sCI
b [13,19] [5.0, 9.6]
Steady-state rate
nM/h
a
2161.2
2sCI
b [18,23]
athe best fit values 6 standard error calculated using a nonlinear regression and
the eqn. 1 [69].
btwo sigma confidence intervals as described in methods section [69].
cthe best fit values 6 standard error calculated using a nonlinear regression and
the eqn. 2.
doi:10.1371/journal.pone.0032293.t001
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apparently small 30% decrease in Ab 1–40 production can have
physiological significance since 30% change in Ab 1–40
metabolism was observed in studies of AD pathogenesis in model
organisms [7,67].
Similar to the results from Michaelis–Menten studies, urea gels
show that gradual saturation with C99 substrate leads to decrease
in Ab 1–40 production (Fig. 4 B–C) with concomitant increase in
production of the longer more hydrophobic Ab products (similar
experiments is also reproduced in studies of FAD mutations shown
later in the text). Different Ab products in each reaction were
quantified by calculating the percentage of each Ab 1-x product
relative to the sum of all Ab products in the corresponding lane
(Fig. 4 C, the same approach was used in similar studies in the past
[37]). Relative to the half-saturated reactions (0.3 mM C99), the
fully saturated reactions (3 mM C99) shows 15% decrease in Ab 1–
40, no significant changes in Ab 1–42, 8% increase in Ab 1–43 to
Ab 1–45, and 15% increase in Ab 1–46 and Ab longer than 1–46.
The observed changes in Ab products are smaller than the
changes calculated from the Michaelis–Menten analysis, since
lower sensitivity of the urea gels did not allow us to use assays with
less than 300 nM C99 substrate.
The changes in Ab products caused by gradual saturation of c-
secretase with its C99 substrate show that the catalytic mechanism
is not the same at sub-saturating and saturating substrate [62].
This could be due to: i) gradual binding of multiple C99 molecules
to c-secretase; ii) C99 dimerization/oligomerization induced by
gradual increase in C99 concentration; or iii) a combination of
those two events. We examine those three possibilities by
measuring dimerization/oligomerization of C99 molecules that
Figure 2. Urea gels show Ab 1-x products in different phases of c-secretase reaction. The reactions were prepared using CHAPSO enriched
c-secretase membranes (total protein 0.25 mg/ml), and saturating concentration of C99 substrate (3.0 mM). The lanes ‘‘Ab std 1-x’’ represents
synthetic peptides as mobility standards. To facilitate detection of the early data points (A) the reaction volume was twenty fold bigger than usual,
and the resulting 1-x Ab products were concentrated about twenty-fold by immunoprecipitation using protein G beads and polyclonal antibodies
specific for the first 5 amino acids. It is necessary to mention that pre-incubation of the assay mix for several hours prior to the start of reaction (i.e.
addition of C99 substrate) does not affect the relative distribution of different Ab products. Therefore, the observed changes are not due to enzyme
denaturation during the course of the reaction.
doi:10.1371/journal.pone.0032293.g002
Figure 3. Michaelis-Menten profiles for AICD, Ab 1–40 and Ab 1–42 in presence of DAPT. CHAPSO enriched c-secretase membranes were
used to measure Michaelis-Menten profiles for total AICD production in presence of 0 nM (N), 70 nM (+) and 150 nM (O) of DAPT. Michaelis-Menten
profiles for Ab 1–40 and Ab 1–42 production were measured in presence of 0 nM (N), 100 nM (+) and 200 nM (O) of DAPT. All profiles have been
analyzed using nonlinear regression and the eqn. 4 (methods). The corresponding best fit values are summarized in Table 2. The gel strips show
different concentrations of the C99 substrate and the corresponding AICD products. Alternating in-between are the parallel control reactions in
which c-secretase was inhibited by a mix of 10 mM of DAPT and LY-411,575 [3,4]. AICD was measured using antiflag M2 antibodies (as shown in the
gel strip). Ab 1–40, and Ab 1–42 were measured using AlphaScreenH as described in methods section.
doi:10.1371/journal.pone.0032293.g003
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dissociation constant Kd is equal to 3362 nM (eqn. 5), which is 10
to 15 fold lower than the Michaelis–Menten constant for Ab 1–40,
Ab1–42and AICD(Table2).Thus,theshiftsinAb productsshown
in figure 4 occur when the majority of C99 molecules are forming
dimers/oligomers (the eqn. 5 can be used to calculate the extent of
C99 dimerization at different C99 concentrations). In summary,
gradual saturation of c-secretase with its C99 substrate (Fig 3) leads
to gradual changes in the Ab products (Fig. 4) due to gradual
increase in the enzyme activity on C99 dimers/oligomers (Fig. 5).
The modulation of c-secretase activity by multiple enzymes-
substrate interactions can be also demonstrated by measuring the
enzyme activity with its C99 substrate in the presence of NotchDE
substrate (Fig. 6). In a simple scenario when one enzyme can bind
only one substrate, NotchDE substrate could be only a competitive
inhibitor of c-secretase activity on C99. We find however that
NotchDE substrate can activate c-secretase reaction on C99
substrate by 85% even when c-secretase is half-saturated with its
C99 substrate ([C99]=0.44 mM)). Such cooperative effect on the
catalytic rates can happen only if both NotchDE and C99
Figure 4. Changes in Ab products caused by gradual saturation of c-secretase. Saturation of c-secretase with its C99 substrate leads to
decrease in Ab40 production with concomitant increase in production of the longer more hydrophobic Ab peptides and Ab42/Ab40 ratio. (A) The
saturation profiles from Fig. 3 were used to calculate the ratio between Ab 1–40 (N) and Ab 1–42 (O) production and the total AICD production. The
ratio curves were calculated using the saturation profiles from Fig. 3 in the absence of DAPT. (B) Urea gels were used to analyze the relative
distribution of different Ab 1-x fragments at half-saturating (0.3 mM) and saturating (3.0 mM) concentrations of C99 substrate. The lane ‘‘Ab std 1-x’’
represents synthetic peptides as mobility standards, the lane ‘‘inhibitor’’ represents parallel control reaction in the presence of 10 mMo fc-secretase
inhibitors DAPT and LY-411,575 [3,4]. (C) The relative intensity of each Ab 1-x peak is shown as a percent of the total sum of all Ab peaks in the
corresponding lane. The intensity of different Ab 1-x products was quantified by transforming the individual bands into a series of peaks using the
‘‘ribbon option’’ in program ImmageQuant 5.0. The resulting peaks and the corresponding baselines were quantified using the ‘‘peak-fit’’ option in
MicroCal Origin 7.0 program.
doi:10.1371/journal.pone.0032293.g004
Figure 5. Oligomerization of C99 substrate. C99 dimerization/oligomerization was measured using aliquots of C99 substrate that had high
activity with c-secretase in CHAPSO enriched membranes. Oligomerization between C99 molecules was measured using AlphaScreenH technology by
coupling both the donor-beads, and the acceptor-beads, to 3D6 antibody (right panel). Increasing concentration of C99 substrate was incubated with
10 nM of 3D6 monoclonal antibodies coupled to either donor or acceptor-beads. Since one epitope can bind only one antibody, the acceptor and
the donor beads can come to proximity and give the AlphaScreenH signal only if C99 dimerization/oligomerization brings the epitopes together
(right panel). A nonlinear regression and the equation 5 (methods) were used to calculate an apparent dissociation constant, Kd=3362 nM [69].
doi:10.1371/journal.pone.0032293.g005
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32293Figure 6. NotchDE substrate can activate c-secretase activity on C99 substrate. c-Secretase activity in CHAPSO enriched membranes was
measured using half-saturating C99 substrate ([C99]=0.45 mM, fresh after purification) in the presence of increasing concentration of NotchDE
substrate (N), and in identical control assays without NotchDE substrate (O). The AICD production was measured using 125-I labeled C99 substrate
and autoradiography as shown on the gel strips (125-I assay was used instead of western blot since both substrates were purified using antiflag M2
epitopes, see methods). Different interactions between c-secretase and its C99 (black helix) or NotchDE (green helix) substrates can be illustrated
using a model mechanism. C99 substrate can be shown as a transmembrane helix [42], while c-secretase can be shown as a bowl-shaped membrane-
imbedded complex [19]. The underlined numbers connect the different complexes with the corresponding activity range on the graph. In a simple
scenario, of one enzyme binding one substrate, NotchDE and C99 substrates could be only competitive inhibitors [62]. We find that NotchDE
substrate can activate c-secretase reaction on C99 substrate (1). Such scenario can happen only if c-secretase can bind both substrates at the same
time (2). NotchDE substrate shows competition with C99 substrate only when its concentration is several folds higher than C99 concentration (3).
Extrapolation of the presented profile shows that close to 10 mM of NotchDE substrate would be needed for a full inhibition (4).
doi:10.1371/journal.pone.0032293.g006
Table 2. Michaelis-Menten parameters for different c-secretase products (Fig. 3)
a.
AICD
a Ab 1–40
a Ab 1–42
a
DAPT 0 nM 70 nM 150 nM 0 nM 100 nM 200 nM 0 nM 100 nM 200 nM
Km, 874 870 1010 620 560 540 780 660 740
nM 6252 6266 6248 688 688 684 6152 660 6140
Vmax 15 10 6.7 5.15 2.93 1.94 4 2.10 1.50
nM/h 61.82 61.5 60.9 60.36 60.22 60.14 60.41 60.09 60.16
athe best fit values 6 standard error were calculated using nonlinear regression and the eqn. 4.
doi:10.1371/journal.pone.0032293.t002
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substrate starts to inhibit enzymatic reaction on C99 substrate
only at higher concentrations. We could not reach sufficiently high
concentration of NotchDE substrate to achieve a full inhibition
(the inhibition constant for NotchDE substrate is expected to be
several fold higher than its dissociation constant or its Km constant
[68] due to competition with C99 substrate as described on p. 214
in ref. [69]).
We also find that DAPT acts as a noncompetitive inhibitor of c-
secretase when the enzyme is approaching saturation with its C99
substrate (Fig. 3). Thus, at the saturating substrate DAPT and the
C99 substrate do not compete for the same binding site on the
enzyme.
Modulation of catalytic activity of c-secretase by free Ab
products in the reaction mix (Fig. 7)
Both, the progress of c-secretase reaction in time (Figs. 1–2) and
the gradual saturation with C99 substrate (Fig. 3) result in increase
in concentration of different Ab products in the reaction mix.
Thus, there is a possibility that the observed changes in the
enzymatic mechanism can be due to Ab products that (re)associate
with c-secretase and modulate its ongoing catalytic mechanism.
We have performed several experiments to test if Ab peptides
present in solution can bind to c-secretase and affect its catalytic
mechanism (Fig. 7).
We find that premixing the reaction mixture with 10 nM
synthetic Ab 1–40 or Ab 1–42 (Fig. 7A) does not affect the relative
difference between Ab 1–40, Ab 1–42, and the longer more
hydrophobic Ab products as it can be seen in Fig. 2 and Fig. 4 B.
We also find that Ab 1–40, Ab 1–42, and the longer Ab products
are not affected when the reaction mix was treated with antibodies
specific for the neoepitopes on Ab 40 or Ab 42 (by binding to Ab
40 or Ab 42 the bulky antibodies could interfere with the repeated
interaction between c-secretase and its Ab products). Even
extremely high concentrations of synthetic Ab 1–38, Ab 1–40,
Ab 1–42, or Ab 1–44 do not affect the rate of AICD production
(Fig. 7B, only AICD production could be measured in these
experiments since the high concentrations of added synthetic Ab
peptides interfere with Ab detection in the urea gels).
In summary, we conclude that Ab peptides present in free
solution do not (re)associate with c-secretase and affect its catalytic
mechanism and the Ab products.
Comparative analysis of enzymatic mechanism of WT
presenilin 1 and FAD mutations G384A and DE9
Comparative analysis of WT presenilin 1 and FAD mutations
could highlight changes in the catalytic mechanism that can lead
to the pathogenesis. We find that relative to the WT presenilin 1,
the total AICD production (i.e. the turnover rates [37]) is about
15% slower for DE9 mutation, and about 60% slower for G384A
mutation (Fig. 8 A). The Km values for AICD fragments are
within experimental error identical (Fig. 8 A). The most significant
difference between the WT and the two mutants is in Ab products
(Fig. 8 B–C). To different extent the mutants favor Ab 1–42 and
the longer more hydrophobic Ab products (Fig 8 B). Different Ab
products in each reaction were quantified by calculating the
percentage of each Ab 1-x product relative to the sum of all Ab
products in the corresponding lane (Fig. 8 C, the same approach
was used in similar studies in the past [37]). DE9 mutant
predominantly generates the longer more hydrophobic Ab
products (i.e. Ab 1–46 and Ab 1–46+), while the shorter Ab
products constitute only about 5–10% (Ab 1–40) and 18–28% (Ab
1–42) of the total Ab. Similar to DE9 the longer more hydrophobic
Ab products are dominant products with G384A mutant. In
difference to DE9, Ab 1–42 is a significant fraction of the total Ab
products with G384A mutant (between 32–40% of the total Ab).
For both mutants Ab 1–42 stands out as the most dominant short
Ab product (Fig. 8 B). In summary, when compared to the WT
presenilin 1, the two FAD mutants show decrease in Ab 1–40 and
increase in the longer more hydrophobic Ab peptides and Ab42/
Ab40 ratio.
Due to mutant’s low activity in Ab 1–40 and Ab 1–42
production, we were unable to achieve the experimental sensitivity
that is required for a full quantitative analysis of the Michaelis-
Menten profiles as we did with the WT enzyme (Fig. 4A).
Nevertheless, the urea gels suggested that for both mutants gradual
increase in substrate saturation results in increase in production of
the longer more hydrophobic Ab. The effect appears to be less
pronounced than with the WT (Fig. 8 B–C). When fully saturated
Figure 7. c-Secretase is not affected by Ab peptides present in free solution. (A) The lanes labeled as ‘‘free reaction’’ represent Ab products
after 4 hours of routine c-secretase reaction at half saturating C99 substrate ([C99]=0.45 mM). The lanes labeled as ‘‘+10 nM Ab 1–42’’ and ‘‘+10 nM
Ab 1–40’’ represent ‘‘free reaction’’ premixed with synthetic Ab 1–42 or Ab 1–40 in a concentration equivalent that corresponds to 4 hours of free
reaction. The lanes labeled ‘‘+21F12’’ and ‘‘+2G6’’ represent ‘‘free reaction’’ that was premixed with antibodies specific for Ab42 or Ab40 respectively.
Both 2G6 and 21F12 antibodies bind the matching Ab peptides very efficiently as indicated by a complete removal of the corresponding Ab bands in
the reactions with protein G beads (samples labeled as ‘‘21F12 and prot. G’’ and ‘‘2G6 and prot. G’’). The lane ‘‘Ab std 1-x’’ represents synthetic
peptides as mobility standards. (B) AICD production was measured at half-saturating C99 substrate (0.45 mM) in assays that were premixed with
increasing concentrations of synthetic Ab 1–38, Ab 1–40, Ab 1–42, or Ab 1–44.
doi:10.1371/journal.pone.0032293.g007
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decrease in Ab 1–40, 9% decrease in Ab 1–42, and 15% increase in
Ab 1–46 and Ab longer than Ab 1–46. Similarly, G384A shows 4%
decrease in Ab 1–40, 10% decrease in Ab 1–42, and 11% increase
in Ab 1–46 and Ab longer than Ab 1–46. Similar to the data shown
in Fig. 4B,WT shows that thesaturated reaction has9%decrease in
Ab 1–40, no significant changes in Ab 1–42, 5% increase in Ab 1–
43 to Ab 1–45, and 14% increase in Ab 1–46 and Ab longer than
Ab 1–46 (WT lanes in Fig. 8 B–C and Fig. 4 B–C show two
independent measurements of the same phenomena).
We used two different classes of c-secretase inhibitors to analyze
how the mutations affect the enzyme structure (Fig. 9 and Table 3).
L-685,458 is a transition state inhibitor that is thought to target the
active site aspartates [15]. With L-685,458, DE9 and G384A show
similar 10–20 fold decrease in inhibition potency relative to the
WT (Fig. 9 and Table 3). Such decrease in IC50 values can be a
result of a loss in binding energy equivalent of one misplaced
hydrogen bond ([62], some illustrative examples can be found in
ref. [15]). Thus, the two mutations result in similar and relatively
small perturbations in the active site structure. Very different
situation is observed with DAPT, an inhibitor that is targeting N-
terminal of presenilin 1 in the transmembrane domain 7 [3]. With
DAPT, DE9 mutation shows approximately twofold decrease in
inhibition potency relative to the WT (Table 3), while G384A
mutation shows about 1000-fold decrease in the inhibition potency
and a low (shallow) Hill’s coefficient [69] (Fig. 9, Table 3). The low
Hill’s coefficient [69] indicates that the mutation leads to structural
heterogeneity (i.e. constrained flexibility) at the DAPT binding site,
Figure 8. AICD and Ab production by WT presenilin 1 and two FAD mutants. CHAPSO enriched c-secretase membranes carrying WT
presenilin 1 or FAD mutants DE9 and G384A have been prepared and analyzed in parallel with all conditions identical. (A) Michaelis-Menten profiles
for total AICD production (i.e. the turnover rates [37]) were measured in parallel using anti-flag aM2 antibodies as shown in Fig 3. (B) urea gels show
the relative distribution of different Ab 1-x products at the sub-saturating and saturating substrate concentrations (5 hour reactions). The lane ‘‘Ab std
1-x’’ represents synthetic peptides as mobility standards, the lane ‘‘inhibitor’’ represents a parallel control reaction in the presence of 10 mMo fc-
secretase inhibitors DAPT and LY-411,575 [3,4] (C) The relative intensity of each Ab 1-x peak is shown as a percent of the total sum of all Ab peaks in
the corresponding lane. The intensity of different Ab 1-x products was quantified by transforming the individual bands into a series of peaks using
the ‘‘ribbon option’’ in program ImmageQuant 5.0. The resulting peaks and the corresponding baselines were quantified using the ‘‘peak-fit’’ option
in MicroCal Origin 7.0 program.
doi:10.1371/journal.pone.0032293.g008
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IC50 values for both DAPT and L-685,458 with the WT enzyme
are very similar to the values measured in cell-based assays [3,15].
Thus, the WT enzyme has very likely same structure around the
inhibitors’ binding sites in our enzyme-based assays and in the
previous cell-based assays [3,15].
Discussion
There is a standing debate whether pathological increase in
Ab42/Ab40 ratio is a result of ‘‘a gain of function for production
of Ab42’’, or ‘‘a loss of function for production of Ab40’’ [20]. We
find that increase in Ab42/Ab40 ratio can be caused by: i) increase
in Ab 1–42 production due to progress of c-secretase reaction
from pre-steady-state to steady-state catalysis (Fig. 1 and 2), ii)
decrease in Ab 1–40 production due to enzyme saturation with its
C99 substrates (Fig. 3–4 and Fig. S3). In both cases, increase in
Ab42/Ab40 ratio and decrease in Ab40 production correlates
with increase in production of the longer more hydrophobic Ab
products. The presented results are consistent with the earlier
studies [37,38,40,48–50]. The molecular mechanisms that can
lead to such changes are elaborated in detail in Fig. 10 and Fig. 11.
The increase in Ab42 production can be attributed to changes in
c-secretase-C99 interaction, so that the initial cleavage takes place
between the amino acids 48–49 rather than between 49–50
(Fig. 10). The increase in the longer more hydrophobic Ab
products can be attributed to decreased ability of c-secretase to
hold and fully process the nascent Ab catalytic intermediates
(Fig. 10 and Fig. 11).
The idea that c-secretase can bind more than one C99 molecule
was presented many times in the past. It has been proposed that
the substrate can translocate from a docking site to the active site
[66,70,71], or that the enzyme has a regulatory allosteric site and
the catalytic site [72,73]. Here we present four different lines of
evidence that c-secretase can bind and cleave multiple substrate
molecules in one catalytic turnover. Namely, i) gradual saturation
with C99 substrate leads to changes in the enzyme mechanism
(Fig. 4); ii) the enzyme shows high activity with substrate dimmers/
oligomers (Fig. 5); iii) C99 cleavage can be activated by NotchDE
substrate (Fig. 6); iv) high magnitude of the pre-steady state burst
(Fig. 1 and Fig. S2). Several studies showed that c-secretase can
cleave C99 dimers [42–45], including C99 molecules covalently
attached to dimers [46]. Therefore, the substrate binding cavity
must be large enough to accommodate more than one C99
molecule (Fig. 11). We propose that binding of multiple C99
molecules into one active site cavity (Fig. 11) is the most
straightforward explanation for the studies that proposed multiple
Figure 9. Inhibition of WT presenilin 1 and FAD mutants by DAPT and L-685,458. CHAPSO enriched c-secretase membranes carrying WT
presenilin 1 or FAD mutations DE9 and G384A have been prepared and analyzed in parallel with all conditions identical. The dose response curves for
DAPT [71] and L-685,458 [15] were measured by following total AICD production using western-blots with aM2 antiflag antibody as shown in Fig. 3.
The results were analyzed using nonlinear regression and the equation 3 (methods). The best fit values and the corresponding statistics are given in
Table 3.
doi:10.1371/journal.pone.0032293.g009
Table 3. Inhibition of WT presenilin 1 and FAD mutants by (Fig. 9)
a.
Inhibitor: DAPT L-685,458
Presenilin 1: WT DE9 G384A WT DE9 G384A
IC50,nM
a 3906179 7346254 3 10
661?10
6 32647 0 7 680 398651
2sCI
b [150, 540] [505, 934] n.a.
c [29,35] [631, 776] [339, 479]
Hill’s coef.
a 0.760.2 1.2160.07 0.5460.25 1.360.1 0.986 0.08 160.13
2sCI
b [0.55, 1] [1.54, 1.07] n.a.
c [1.1, 1.4] [0.9, 1.06] [0.86, 1.14]
athe best fit values 6 standard error were calculated using nonlinear regression and the eqn. 3.
btwo sigma confidence intervals as indicated in methods section [69].
ccannot be calculated due to the limited data range.
doi:10.1371/journal.pone.0032293.t003
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and the present results (Fig. 1, 2, 3, 4, 5, 6).
Increase in Ab42/Ab40 ratio, and increase in production of the
longer more hydrophobic Ab products appears to be a shared
feature between different conditions that could support develop-
ment of the disease. To different extent, both of these features can
be observed: i) when c-secretase is saturated with it C99 substrate
(Fig. 4, and Fig. S3); ii) when DE9 and G384A FAD mutations are
compared to WT presenilin 1 (Fig. 8B); and iii) when Aph1A
subunit is compared to Aph1B subunit of c-secretase [22]. Ab 1–
43 can be more toxic than Ab 1–42 in model organisms and in
cells [59]. Our ability to explore pathophysiology of Ab products
longer than Ab 1–42 is in a large part limited by our ability to
understand the enzymatic mechanism that leads to their formation
[59,61]. The longer Ab peptides are highly hydrophobic, difficult
to measure, and only a small fraction of reported studies have met
the experimental challenges [22,37,40,48–50]. Nevertheless the
longer Ab peptides are catalytic intermediates that can give
valuable insights to the pathogenesis [59,61] and the catalytic
mechanism (Fig. 10). Studies of the longer Ab can also provide
answers to many of the earlier confusions that came from studies
that rely only on measurements of Ab42, Ab40, Ab38 and/or
Ab42/Ab40 ratio [46,48,61]. The longer more hydrophobic Ab
products can also explain why forced dimerization of C99
substrate leads to decrease in the secreted Ab products and
increase in AICD production [46].
Quantitative studies of the enzyme mechanism are possible only
in enzyme-based assays that allow control of the reaction time
(Figs. 1 and 2), and the extent of enzyme saturation with its
different ligands (Figs. 3, 4, 5, 6, 7 and 9) [62]. The enzyme-based
assays can be correlated with cell-based assays. For healthy cells
the most frequently quoted value for Ab42/Ab40 ratio is 1:10
[1,48]. Our enzyme-based assays show that the closest similarity
with the cell-based assays can be achieved at the lowest saturation
with C99 substrate (Fig. 4A), and in the early pre-steady-state (i.e.
the first 10 minutes of reaction) (Fig. 1–2). This is not surprising,
since low saturation and pre-steady state conditions are closest to
the general conditions that exist in cells [74–76]. In cells enzymes
Figure 10. Steps in the catalytic cycle of c-secretase. The model illustrates the basic biophysical principles of processive cleavages and
intramembrane proteolysis [11,37,40,48,49,51]. C99 substrate can be shown as a transmembrane helix [42], while c-secretase can be shown as a bowl-
shaped membrane-imbedded complex with its active site aspartates in the central aqueous cavity [11,18,19]. The initial AICD cleavage (Fig. 1) takes
place between amino acids 48–49 or 49–50 [37], just under the membrane surface [42], in a dynamic section that has a tendency to destabilize the
transmembrane helix ((C1-.C4), [58]). The result is a soluble AICD fragment, and a hydrophobic Ab fragment with its negatively charged carboxyl-
terminal trapped below the membrane surface (C3-.C4). Thus, the negatively charged carboxyl-terminal is in an energy gap that is forcing it to the
interface between the hydrophobic enzyme core and the hydrophilic central aqueous cavity. The opposing force comes from the hydrogen bonds
that tend to stabilize the transmembrane helix (C4). The Ab peptides have a highly dynamic structure that can vary from a-helix to random-coil [51–
55,57]. Such structural changes can drag small parts of the hydrophobic Ab peptides to the active site aspartates following the negatively charged
carboxyl-terminus in the central aqueous cavity ((C4-.C7), [11]). Thus, the whole process can be driven by entropy and/or by repulsive forces
between negative charges on the active site aspartates and the carboxyl-terminal on the nascent Ab [51–54,57]. There is no need for active use of
cell’s energy. The result is a sequence of processive cleavages of hydrophobic tri-peptides [48] that does not require a full exposure of the
hydrophobic substrate to the aqueous catalytic site [11]. The initial cleavage at 49–50 site leads to Ab 49–46–43–40 sequence, while the initial
cleavage at 48–49 site leads to Ab 48–45–42–38 sequence [37,40,48,49]. It is very important to realize that the most frequent end-products Ab 1–40
and Ab 1–42 have more than a half of the original hydrophobic transmembrane helix of C99 (C6-.C7). Such products are highly unlikely to
spontaneously dissociate from the hydrophobic c-secretase to the hydrophilic extracellular space (C7c). Furthermore, the peptides are too short to
form a transmembrane helix (C7a) [62], while the fully extended structures (C7b) can not be stabile due to unsatisfied hydrogen bonds in the peptide
backbone [62]. For the same reasons the nascent Ab-peptides (C1-.C6) can not be spontaneously released from c-secretase. The hydrophobic Ab
products can dissociate from c-secretase only by interacting with a carrier protein, or by forming an Ab bundle as in Fig. 11. The carrier protein is
expected to facilitate catalytic rates since dissociation of Ab products is the rate-limiting step (Fig. 1, and Fig. S1). Thus, possible candidates for the
carrier protein can be the proteins identified by He and coauthors [93], apo-lipoprotein E [5], PrP C [94], or some other surface proteins [60].
doi:10.1371/journal.pone.0032293.g010
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concentrations [74–76] (we have developed experiments that show
that c-secretase is far below saturation in cells, a manuscript is in
preparation). Such setting is the most suitable for fine tuning of cell
physiology since even the smallest change in any parameter can
give a direct response from the related parameters [62,74]. In the
future we have to increase the sensitivity of our assay to improve
measurements at low saturation (,100 nM) and in pre-steady-
state conditions (,8 min). Such strategy can allow us to address
other potential concerns about the differences between cell-based
and enzyme-based assays [48], but also to correlate pre-steady
state studies of c-secretase (Figs. 1, 2, 3, 4) with the biophysical
studies of C99 and different Ab peptides [47,51–55,57].
Relatively high C99 concentration is needed to saturate c-
secretase in the enzyme-based assays (Fig. 3 and [22,37,38]) since
formation of the enzyme-substrate complex depends on free-
diffusion in three-dimensions in a highly diluted protein solution
(0.25 mg/ml). In cells, c-secretase and C99 molecules are
constrained in two-dimensional membranes, most likely in narrow
membrane rafts [77] and multi-molecular complexes [78], in a
medium with extremely high protein concentration (.200 mg/ml,
[79,80]). Both, the limited diffusion and the molecular crowding
effects can facilitate the component’s association rates and the
interaction energy by several orders of magnitude [79,80]. Thus in
cells the enzyme-substrate complex is formed under influence of
local C99 concentrations [79,80], that cannot be directly
compared with C99 concentrations in whole cell-extracts or the
enzyme-based assays (Fig. 3). Nevertheless, different enzyme-based
studies (Fig. 4 and [37,38]), and different studies on humans,
experimental animals, and cells have shown that in all cases
gradual saturation of c-secretase leads to molecular events that
have been associated with the pathogenesis [23–35].
C99 dimerization/oligomerization has been observed in cells
over-expressing C99, and with purified C99 [42–45,47]. It
remains unknown to what extent endogenous C99 substrate is
dimerized/oligomerized in healthy cells [81]. Since dimerization
affects Ab42/Ab40 ratio [42–46] and other physiological
processes [8,81–83] it can be expected that the cells have
developed some physiological mechanisms that control C99
dimerization. Cell-free assays do not have the physiological
processes that can prevent C99 dimerization (Fig. 5), however
different dilutions of C99 substrate represent different extent of
enzyme saturation with C99 dimers/oligomers (eqn. 5, methods).
Comparisons of WT presenilin 1 with DE9 and G384A FAD
mutants (Fig. 8–9) gave us a glimpse into structural changes that
could lead to the pathogenic changes in Ab products. G384A and
Figure 11. Multiple C99 molecules bound to c-secretase can facilitate the pathogenesis. Multiple C99 molecules bound to c-secretase can
affect the catalytic mechanism and contribute to the neurotoxic events. Multiple C99 molecules bound to the enzyme (1) could interact just as free C99
molecules [42–46]. Such interactions can influence the initial AICD cleavage and thus control the difference between Ab 49–46–43–40 or Ab 48–45–42
cleavage paths (Fig. 10). If multiple C99 molecules are cleaved in parallel, the result will be a bundle of nascent Ab peptides (3), or even a mixed bundle of
C99 andnascent Abpeptides(2).AllofthoseinteractionscanbeaffectedbythesamestructuralforcesthatcontrolinteractionsbetweenAbpeptides in free
solution.Thus, there could be a preferred number of peptides in thebundle [52,53],anda preferred ratio between Ab40, Ab42, and the longer Ab peptides
[56]. Any of those can affect dynamic structural changes that control the processive cleavages, and ultimately the type of Ab products (Fig. 10). Packed
together the nascent Ab peptides can undergo a series of structural changes so that their b-genic amino acids (Thr, Val, Ile) can initiate formation of
extended b-sheet bundles (3-.4) [51–54,57,58]. This can drive transition from the a-helix structure of C99 to the b-sheet structure of Ab oligomers [51–
54,57,58].The whole processcan be chaperonedandaccelerated by the enclosurewithin theenzyme structure. Some functional and evolutionallinks have
been observed between chaperones and rhomboid intramembrane proteases [95,96]. Unlike single amyloid peptides (Fig. 10), the hydrophobic b-sheet
bundles can be easily released into the lipid bilayer (5–.6). The bundles can be stabilized by hydrogen bonding between the peptides’ backbones so that
their hydrophobic amino acids can face the lipid bilayer [51]. The released b-sheet bundles can accumulate to toxic levels by causing disruption of
membraneintegrity(i.e.fluidity,lipidraftsandiongradients[51,97]).Thus,theneurotoxicprocessescanstartdirectlyinthemembranewheretoxicamyloid
peptides are produced, rather than in the extracellular space as it was suggested in the original amyloid hypothesis and its subsequent derivatives [51].
Extracellular amyloid fibrils can be the end result of chronic toxic overload and the final membrane breakdown (7)[ 5 1 ] .
doi:10.1371/journal.pone.0032293.g011
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have very different effect on the enzyme structure around the two
active site aspartates [13]. G384A is a mutation in a highly
conserved active site loop GXGD next to the active site aspartate
D385 [11,13,16]. This apparently subtle change is the only
mutation at that position that can give an active enzyme
[11,13,16]. DE9 is a mutation at a splice acceptor site that results
in a deletion of a link between the two transmembrane helixes that
carry the active site aspartates (amino acids 290–319 [13,84]). DE9
mutation appears to be less pathogenic than G384A. DE9 leads to
onset of Alzheimer’s disease at an average age of 45.5, with death at
an average age of 51.2 [85]. G384A leads to onset of Alzheimer’s
diseaseat an average age of 34.9, with death at an average age of 42.2
[85].
The two mutations have relatively small effects on the total
turnover rates (Fig. 8A), and the structure around the active site
aspartates (Fig. 9 and Table 3). The most significant difference
relative to the WT is in distribution of different Ab products (Fig. 8
B–C). High prevalence of the longer Ab products indicate that the
two mutations affect the enzyme’s ability to hold the nascent Ab
catalytic intermediates before they can be fully processed to the
shorter Ab products (Fig. 10 and Fig. 11). Relatively large fraction
of Ab42 indicates that G384A mutation specifically supports
structural changes that favor amino acids 48–49 as the initial
cleavage site (Fig. 10). Surprisingly, G384A mutation next to the
active site aspartates D385 has bigger effect on the inhibitor
targeting the N-terminal section of transmembrane 7, than on the
inhibitor targeting the active site aspartates (Fig. 9 and Table 3).
The surprising difference in sensitivity to different classes of c-
secretase inhibitors indicates that G384A mutation is not a local
mutation in the highly conserved active site loop [11,16]. More
likely scenario is the proposal that G384A mutation can disrupt
the sliding interactions between the transmembrane helixes 6 and
7 [11,16]. In summary, our results suggest that FAD mutations
primarily affect the enzyme’s interaction with the nascent Ab
catalytic intermediates and C99 substrate (Fig. 10), while there is
relatively little effect on the active site aspartates.
We can use the presented conclusions to contemplate about
mechanism of action for known inhibitors of c-secretase and about
possible alternative drug-design strategies [3,4]. Based on
presented arguments a successive therapy needs to decrease the
extent of enzyme saturation with its C99 substrate. Thus, an
effective drug would be a compound that will increase the Km for
C99 substrate with a minimal effect on the turnover rate for Ab 1–
40; i.e. a standard competitive inhibitor for Ab 1–40 [62].
Noncompetitive inhibitors such as DAPT (Fig. 3) can have exactly
opposite effect from desired. Noncompetitive inhibitors will lead to
decrease in enzyme catalytic capacity, which will make the enzyme
saturated even at the lower levels of its C99 substrate (remember
that maximal activity is equal to the total enzyme concentration
multiplied by its turnover rate, p.p. 105–109 in [62]). Consistent
with the presented proposal, different genetic manipulations have
shown an increase in Ab42/Ab40 ratio when the total catalytic
capacity of c-secretase in cells is decreased [33,35], while the
opposite effects are observed when the enzyme catalytic capacity is
increased [34]. The ability of noncompetitive inhibitors to
facilitate the progress of Alzheimer’s diseases also depends on its
pharmacokinetics and pharmacodynamics properties. Phase III
clinical trials on 2600 patients showed that semagacestat can
facilitate cognitive decline that is characteristic for the disease [21].
Preclinical studies of semagacestat have never been released [86].
However there is a good possibility that semagacestat is a
noncompetitive inhibitor just like DAPT (Fig. 3) based on the
structural [3,4] and the functional similarities [39–41].
In the future all c-secretase inhibitors should be tested in the
enzyme-based studies to avoid unnecessary harm to patients and
costly failures in clinical trials. The key criteria in screening for
effective leads should be competitive inhibition and preservation of
Ab40/AICD ratio (Fig. 4). The two screening criteria should be
selective for favorable Ab42/Ab40 ratios, the short Ab products
(Fig. 4), and the preserved functioning of different signaling
pathways [3,4]. The proposed strategy is encouraged by the
observations that the same disease promoting changes in the Ab
products come with very different changes in the total AICD
production (which is equal to the total enzyme activity). Saturation
of WT c-secretase with its C99 substrate leads to an increase in
total enzyme activity and AICD production (Fig. 3), while FAD
mutations lead to a decrease in total enzyme activity and AICD
production (Fig. 8). c-Secretase complex containing Aph1A
subunit shows pathogenic changes in Ab products relative to
Aph1B complex with almost no difference in AICD activity [22].
Conclusions
We propose that gradual saturation of c-secretase with its
substrate can be the pathogenic process in different alleged causes
of Alzheimer’s disease (Fig. 11). Studies on humans, experimental
animals, and cells described some of the conditions that can lead to
gradual saturation of c-secretase and the pathogenesis. Namely: i)
increased expression of the APP gene [28–30], or any other
increase in APP metabolism [8,36]; ii) increased activity of b-
secretase [23–27], or the Swedish mutation in the APP sequence
[31,32]; iii) changes in the expression of active c-secretase [33–36];
iv) insufficient clearance of Ab products [7,36]. This list is likely to
grow in the future as we learn more about the factors that control
APP metabolism [8,36]. Saturation can be induced even at
normally sub-saturating substrate if the enzyme is exposed to
noncompetitive inhibitors such as DAPT (Fig. 3) [3,4], or to its
alternative substrates such as NotchDE (Fig. 6)
Materials and Methods
Cell cultures
Cos1 cells were obtained from ATCC, while MEF (mouse
embryonic fibroblasts) cells were obtained from the previous
studies [18]. The cells were grown in DMEM media (Invitrogen)
supplemented with 10% fetal calf serum (Sigma). All cell cultures
were propagated by reseeding the cells every three days using 1%
trypsin (Sigma).
Materials
Antibodies used in these studies were: 82E1 (Takara BIO, cat.
number 10323) prepared to recognize the first 16 N terminal
amino acids on human C99 or Ab fragments [50]. 3D6, prepared
against the first 6 N-terminal amino acids in human C99 or Ab
fragments [87]; 2G3, a monoclonal antibody that reacts strongly
with Ab40 but has essentially no cross-reactivity with Ab42 [88],
21F12, a monoclonal antibody that reacts strongly with Ab42 but
has essentially no cross-reactivity with Ab40 [87]. Anti-flag aM2
monoclonal were purchased from Sigma-Aldrich (product number
F2555).
c-Secretase inhibitors DAPT (N-[N-(3,5-difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester) and L-685,485 ({1S-benzyl-
4R-[1S-carbamoyl-2-phenylethylcarbamoyl-1S-3-methylbutylcar-
bamoyl]-2R-hydroxy-5-phenylpentyl} carbamic acid tert-butyl
ester) were purchased from Calbiochem. CHAPSO (3-[(3-
cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfo-
nic acid) used in these studies was always kept on 4uC, and its shelf
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xyethyl)amino)acetic acid), PIPES (1,4-piperazinediethanesulfonic
acid), Tricine (N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine),
and Tween 20 (Polyoxyethylene (20) sorbitan monolaurate) were
purchased from SigmaAldrich.
Preparation of C99 substrate and NotchDE substrate
Both human C99 and human NotchDE substrates were
prepared as earlier described [22,89]. Briefly, COS1 cells were
transiently transfected with pSG5 vector (plasmid Stratagene,
SV40 early promoter) carrying C99 or NotchDE sequences with
3xFLAG sequence at its C-terminus. Fifteen hours prior to harvest
the cells were treated with 10 mMo fc-secretase inhibitor GM6001
(CalBiochem, cat. # 364206) to prevent production of C83-
3xFLAG. The scraped cells were re-suspended in 50 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40 (NP40 (IgepalCA-
630): Sigma), plus complete protease inhibitor mixture (Roche)
and incubated on ice for 1 h. Membrane-solubilized protein
fractions were obtained by ultracentrifugation at 245,0006g for
20 min. Immunoaffinity purification was carried out with the anti-
FLAG M2-agarose beads (Sigma), according to the manufacturer’s
protocols. APP C99-36FLAG was eluted in 100 mM glycine HCl,
pH 2.7, 0.25% n-dodecyl b-D-maltoside (Sigma) and immediately
neutralized to pH=7 by adding 1M Tris-HCl, pH=8.0. The final
substrate concentration was determined based on i) A280
absorbance and calculated extinction coefficient 5.96 10
3
M
-1 cm
–1, and ii) based on BioRad Bradford reagent with
correction for BSA standard as indicated by the manufacturer.
The two methods give within experimental error consistent results.
For 125-I assays, Perkin-Elmer Iodogen kits were used to label
500 mlo f1mM of fresh purified C99 with 1 mCi 125-Iodine in
30 minutes. Labeled C99 molecules were separated from free 125-
I using PerkinElmer PD 10 columns. The labeled C99 was
concentrated and used immediately in c-secretase assays.
Preparation of cell membranes with c-secretase (i.e.
microsomal fractions)
MEF cells, or MEF double knockout for endogenous presenilin
transduced with human WT, dE9 and G384A presenilin 1 [85],
were grown to confluence, scraped, and collected in pellets by
centrifugation at 10006g for 5 min. The cell pellets were re-
suspended in 20 mM Pipes pH=7.0, 140 mM KCl, 0.25 M
sucrose, 5 mM EGTA, plus 1X Roche protease inhibitors cocktail,
so that the total protein concentration was 10 mg/ml. Re-
suspended cells were subjected to more than 20 passages in
8.010 mm cell-cracker. The resulting cell extract was subjected to
10 min centrifugation on 20006g to remove large debris, and the
fragmented membranes were collected as pellets after centrifuga-
tion for 1 hour at 100 0006g, and stored at 280uC.
c-Secretase activity assays using CHAPSO enriched
membranes
c-Secretase assays using CHAPSO enriched membranes were
performed essentially as earlier described [22,37,48,89]. Briefly,
microsomal fractions (protein concentration 10 mg/ml) from
different MEF cells were solubilized in 1% CHAPSO buffer
(50 mM Pipes, pH 7.0, 0.25 M sucrose, 1 mM EGTA, 16Com-
plete protease inhibitor mixture (Roche)) and incubated on ice for
1 h. CHAPSO was always prepared as 1% w/v fresh from a
powder stock that was less than 6 months old and kept at 4uC
(freshness is crucial for high activity). Next, the membrane-
solubilized protein fractions were obtained as supernatant by
ultracentrifugation for 1 hour at 100,0006g. The prepared
CHAPSO enriched membranes were diluted two fold with
50 mM Pipes pH=7.0, 0.25 M sucrose, 1 mM EGTA, 0.1%
phosphatidylcholine, and 0.0125% phosphatidylethanolamine,
plus 16Complete protease inhibitor mixture (Roche), and left on
37uC for two to three hours. This incubation can increase the
measured activity by up to 70% since it can accommodate slow
reassembly of c-secretase components that is induced by the
transition from 1% CHAPSO to 0.25% CHAPSO [90]. The
reactions were started by adding C99 substrate in desired
concentration, the added volume was adjusted so that: i) the final
CHAPSO concentration was 0.25%; ii) and final concentration of
membrane proteins was 0.25 mg/ml. Fresh C99 substrate that is
used immediately after purification gives the best opportunity to
observe described enzymatic features and the highest activity. The
assay mix was prepared in low adhesion microcentrifuge tubes, the
volume was usually 25 mL. To increase sensitivity in early data
points detection, and at low enzyme saturation, the assay volume
was increased up to 400 mL, and the resulting reaction products
were concentrated by immunoprecipitation before the gels were
loaded. The reaction mix was incubated at 37uC, the time was
optimized for each experiment. The AICD production remains
linear for 6 hours at saturating substrate. The reaction specificity
was confirmed by running identical parallel reactions that have
been saturated with inhibitors specific for c-secretase; 10 mM LY-
411,575 and 10 mM DAPT [3,4].
AICD detection with anti-flag aM2 monoclonal antibody
or autoradiography with 125-I
AICD assays using western-blots with anti-flag aM2 monoclo-
nal antibody, or 125-I labelled C99 autoradiography were
performed as earlier described [22,37]. To keep the C99 bands
visible on gels in difference to the previous studies the reaction
aliquots were not subjected to methanol /chloroform extraction.
Briefly, the samples were separated on Nu-PAGE 12% Bis/Tris/
MES/SDS-page gels (Invitrogen) at 150 V for 55 min. For 125-I-
C99 assays the gels were dried and exposed for 1–2 hours to
europium intensifying screens for autoradiography. For western-
blot assays the gel was transferred to nitrocellulose membrane
(protean pore size 0.1 mm), blocked by TBS 1% BSA, and stained
with anti-flag aM2 monoclonal antibody (25 nM). Following the
washes with TBS +0.1% Tween 20, the membranes were
subjected to 25 nM GAMIR (MolecularProbes), washed, and
read using fluorescence at 800 nM. In all assays, the band intensity
was determined using the ‘‘ribbon-option’’ in ImageQuant 5.0
program. The resulting peaks and the corresponding baseline were
quantified using the ‘‘peak-fit’’ option in MicroCal Origin 7.0
program. The AICD was quantified by comparing its signal
intensity with the intensity of the corresponding C99 band (i.e.
known C99 concentration). The linear range and the signal
calibration were further tested using known concentrations of C99
(as shown in Fig. 3), and proportional dilutions of the reaction
aliquots.
Ab1-40 and Ab1-42 detection using AlphaScreenH
Ab 1–40 and Ab 1–42 have been measured quantitatively
following previously described AlphaScreenH approach [91], with
some modifications to accommodate to our experimental needs.
Briefly, AlphaScreenH signal is produced by activated oxygen in a
laser induced photochemical reaction when antibodies carrying
acceptor-beads and donor-beads bind two epitopes that are less
than 20 nM apart. In our case, the acceptor-beads are coupled to
antibodies specific for the C-terminal region of analyzed Ab 1-x
peptides, while the donor beads are coupled to antibodies specific
for the N-terminal (3D6). Synthetic Ab 1-x peptides of known
How c -Secretase Can Generate Neurotoxic Events
PLoS ONE | www.plosone.org 13 March 2012 | Volume 7 | Issue 3 | e32293concentration were use to calibrate the measured AlphaScreenH
signals and the corresponding linear range (usually between 0.25
to 20 nM). It is important to notice that AlphaScreenH signal
measured with synthetic Ab standards does not accurately
represent Ab products in reaction aliquots. There are two major
differences: i) C99 substrate in reaction aliquots competes with Ab
products for 3D6 antibodies, which leads to a decrease in the
signal intensity and a smaller linear dynamic range; ii) aggregation
between Ab products (and possibly between C99 molecules and
Ab products) can artificially increase signal intensity, especially at
the low concentrations of Ab products. In the case of aggregation,
the AlphaScreenH signal is artificially enhanced since it is not only
due to antibodies that bind at the C-terminal and the N-terminal
region of one Ab product, but also due to antibodies that bind to
the C-terminal and the N-terminal region of different Ab product
that are brought together by aggregation.
The problem of competition between Ab products and C99
substrate for 3D6 antibodies can be addressed by calibrating the
AlphaScreenH signal in presence of fixed concentrations of C99
substrate. In Michaelis-Menten experiments concentration of C99
substrate is varied and therefore its effects on 3D6 antibody can be
variable. Thus, prior to the AlphaScreenH measurements all
reaction aliquots have been diluted so that the final concentration
of C99 is less than 5 nM. The corresponding standard curves were
prepared with less than 5 nM C99. The effects of aggregation of Ab
products on AlphaScreenH signal were more difficult to address
sincethe aggregation between Ab productsdependsontime and the
solution [56]. Those can not be replicated with confidence using
synthetic Ab peptides. We found empirically that the aggregation
artifacts become increasingly more present in Ab solutions with
time. These artifacts result in an unacceptable scatter of the
measured signal, and there is no linear decrease in signal intensity
with proportional dilutions of the reaction aliquots. The lower the
enzyme activity, the more troublesome are those effects. Thus, a
standard rectangular hyperbola is not observed when reaction is
increasingly less saturated with its C99 substrate (usually a lag, or
abrupt stepwise changes in signal intensity are observed at the low
substrate concentrations). Increasingly more serious aggregation
artifacts are observed in reaction aliquots that used C99 substrate
that has been fast frozen and stored at 280uC for increased time
periods (especially more than a week). Such measurements gave a
high scatter at the low substrate concentrations despite of a high
activity at the high substrate concentrations. The AlphaScreenH
readouts do not follow a linear response at any dilution of the
reaction aliquots. When c-secretase assays are performed with C99
substrate immediately after the purification, the measured reaction
aliquots give the highest AlphaScreenH signal, with a very low
scatter, and readout that is linearly proportional to the size of the
reaction aliquot. A standard rectangular hyperbola is observed
when the reaction is gradually saturated with C99 substrate.
Analysis of Ab 1-x peptides by Urea Gels
Urea gels were used to analyze to what extent Ab peptides
longer than Ab 1–42 represent the total Ab. Urea gels 8M/10
T%/5% C/ SDS-PAGE were prepared, used, and processed as
earlier described [22,49,92]. Briefly, mini-gels were prepared in
three layers, running gel Tris/H2SO4 pH=8.1 (5.8 cm), stacking
gel BisTris/H2SO4 pH=6.7, and comb gel BisTris/Bicine
pH=7.7. The continuous voltage electrophoresis was adjusted
to 100 V (65–30 mA), the run time was about 1 h 35 min, until
dye front was 5 mm from the bottom edge. At the end of
electrophoresis the prepared gel was transferred to PVDF
membranes in 90 min using Invirtogen semi-dry transfer units.
Following the transfer the membrane was boiled for 5 min in PBS,
and blocked with RotiBlockH (Carl Roth) according to the
manufacturer instructions. The blocked membranes were exposed
to 20 nM 82E1 antibody overnight, and then washed with
TBS+0.1% Tween 20, three times 10 minutes. The second
membrane incubation was 4 hours long in the presence of
20 nM of biotinylated goat-antimouse IgG prepared in TBS
(TBS, Tris/HCl pH=7.6, 150 mM NaCl). The third incubation
was with 10 nM streptavidin-horse-radish- peroxidase. The gel
was developed using a gel imaging devices with CCD camera and
chemiluminescence reagents according to the manufacturer
instructions. The band intensity on the acquired gel images were
quantified using the ‘‘ribbon-option’’ in ImageQunat 5.0 program,
and the resulting peaks and the corresponding baselines were
resolved and quantified using the ‘‘peak-fit’’ option in MicroCal
Origin 7.0 program.
Preparation of Ab 1-x standards
All Ab 1-x standards were prepared by the solid phase synthesis
as a lyophilized powder. The powder was dissolved in a small
amount of trifluoro-cyclohexane, that was subsequently slowly
evaporated under argon, re-suspended in TBS, and frozen on
280uC in aliquots that were used only once.
C99 dimerization/oligomerization assays using
AlphaScreenH approach
PerkinElmer’s acceptor and donor beads were coupled to 3D6
antibodies following the manufacturer’s instructions. The prepared
acceptor and donor beads were incubated with different dilutions
of fresh C99 substrate that gave high activity in different activity
measurements (Fig. 3). After three hours of incubation 20 mL
aliquots were used to measure the AlphaScreenH signal using 384
well plates and PerkinElmer instrument. It is important to notice
that if the concentration of C99 is more than 20 fold higher than
the concentration 3D6 antibody the signal will start dropping even
in the case of interaction. The decrease in the signal intensity is a
result of dilution of the labeled antibodies in the large excess of
interacting C99 molecules.
Data Analysis
All experimental results were analyzed using MicroCal Origin
7.0 program, using non-linear least square regression, and the
equation that represent specific mechanism. All results are
reported as the best fit value 6 standard error with two sigma
confidence intervals shown in square brackets (i.e [x, y]) [69].
Briefly, the standard error indicates precision (i.e. random errors)
for each method, the two sigma confidence intervals indicate the
ability of given experimental setup to resolve specific parameters.
The random error for presented techniques is low, as indicated by
a low scatter from the best fit values. We optimized our
experiments to maximize the resolution of each parameter by
increasing the number of independent data points with even
distribution throughout the full range of measured profiles (i.e.
maximizing the number of degrees of freedom [69]).
The relative intensity of AICD, C99 and Ab 1-x products in
different gels was quantified by transforming the individual bands
into a series of peaks using the ‘‘ribbon option’’ in program
ImmageQuant 5.0. The resulting peaks and the corresponding
baselines were quantified using the ‘‘peak-fit’’ option in MicroCal
Origin 7.0 program. The linear dynamic range for each
measurement was tested by quantified by using different dilutions
of the analyzed samples.
The data representing pre-steady-state burst have been
analyzed using the corresponding equation [62,63]:
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where [P](t) is product at time t, ESo is the apparent initial enzyme-
substrate concentration based on the burst intercept (p. 238 in
[62]), p is the pre-steady-state rate, and k is the steady-state rate
(i.e. k=kcat?ESo, kcat, the turnover rate, ESo [62]). The initial
reaction lag was analyzed using a model equation for enzyme
hysteresis [63]:
P(t)~k:t{
k:(1{e{q:t)
q
ð2Þ
where [P](t) is product at time t, k is the catalytic rate constant in
the steady-state (i.e. k=kcat?ESo, kcat, the turnover rate, ESo the
initial concentration of enzyme-substrate complex). The lag
transition rate is labeled as q. All standard dose response curves
were analyzed using a standard equation [69]:
S(x)~Bz
(T{B)
1z10(x{x1):h ð3Þ
where, x represents logarithm of inhibitor concentration, S(x) is
measured signal at inhibitor concentration x, B is the signal at
inhibitor concentration zero, T is the highest signal achieved.
Logarithmic values of the IC50 are labeled with x1,w h i l eh represent
the corresponding Hill’s coefficient. Changes in catalytic rates as a
function of enzyme saturation with its C99 substrate was analyzed
using nonlinear least square and the Michaelis-Mentenequation[62]:
v~
V max:½S 
Kmz½S 
ð4Þ
v is measured reaction rate, Vmax is the maximal rate at the
saturating substrate, Km is the Michaelis-Menten constant, [S] is
concentration of C99 substrate. Apparent dissociation constant Kd
for interaction between C99 molecules was calculated by deriving
a quadratic equation [69] that is specific for dimerization:
Sm{So
Sf{So
~
(2LzKd)z
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(2LzKd)
2{4L2
q
2
ð5Þ
where Sm represent measured signal, So initial signal and Sf the
final signal at the plateau. L represents C99 concentration and Kd
corresponds to the apparent dissociation constant.
Supporting Information
Figure S1 Numerical simulation of different Ab catalytic
intermediates in c-secretase reaction. (A-C). Computer
programs KINSIN [98] and GEPASI [99] use numerical
simulation to generate model results that allow comparisons
between the proposed enzymatic mechanism and the actual
experimental results (Fig 1 and 2). (A) The scheme shows catalytic
cycle for the processive cleavages of C99 substrate by c-secretase
in its most basic form (Fig. 10). Such cycle is easy to simulate, the
enzyme (E) has only one substrate (S), and the catalytic
intermediates have only two possible fates: irreversible proteolytic
cleavage or irreversible dissociation (Fig. 10). The simulation of
relative difference between different Ab catalytic intermediates is
based on the ratio between the cleavage rates and the dissociation
rates, following the experimental data shown in supplement
figure 3. For example, if Ab 49 is 5% of the total Ab, the ratio
between the rate of cleavage (i.e. Ab 49 to Ab 46) and the rate of
dissociation of Ab 49, should be 95 over 5. The same approach is
continued to simulate the time profiles for Ab 46, Ab 43, Ab 40,
and Ab 37 using the percentages numbers shown in the scheme.
The experimentally measured time profiles for AICD and Ab 40
(Fig 1) are the reference for the required time scale, i.e. the values
for the chosen rate constants are calculated so that the simulated
profiles for AICD and Ab 40 profiles maximally overlap with the
experimental profiles (k1 rate corresponds to pre-steady-state rate
in Table 1, the steady-state rate is the slowest step in the cycle).
Finally, the extent of accumulation of each intermediate depends
on ratio between its rate of formation and rate of degradation (as
illustrated in detail on p. 145 in Ref. [62]). Those ratios are not
known for the catalytic intermediates of c-secretase . Thus, we
chose to simulate situation with 1:1 ratios which represents
intermediate accumulation of each intermediates (i.e. the rate of
formation and degradation of Ab 49, Ab 46, Ab 43 are equal).
The results in Fig. 2 indicate that it is very likely that the actual
ratio is in favor degradation (i.e. minimal accumulation of reaction
intermediates as shown on p. 145 in Ref. [62]). (B-C). Panel B
shows an attempt to simulate data in Fig. 1, the panel C shows
only the early data points. The simulation shows that the longer
Ab are most dominant in the early stages of the reaction and
progressively decline with the reaction progress to steady-state.
The actual experiments showed an opposite situation (Fig 1–2), Ab
40 dominates in the pre-steady-state, and that longer Ab fragments
start to accumulate only with the reaction progress to the steady-
state (Fig 1 and 2). Thus, c-secretase can not be described as an
enzyme that follows the same processive mechanism in the pre-
steady-state and the steady state. The discrepancy between the
model data and the experimental data supports our proposal that
progress of c-secretase reaction in time leads to a change in the
enzyme’s ability to process and hold the longer Ab catalytic
intermediates.
(DOC)
Figure S2 Titration of c-secretase activity using potent c-
secretase inhibitor LY-411, 575. Highly potent enzyme inhibitors
can be used to estimate concentration of active enzyme (p 206. in ref
[62]). LY-411, 575 is one of the most potent c-secretase inhibitors, its
IC50 in cell-based assays is about 100 pM. Thus, LY-411,575 can be
used to estimate c-secretase concentrations when the active enzyme
concentration is above 100 pM. We find that about 1 to 2 nM of LY-
411,575 can completely abolish c-secretase activity in CHAPSO
enriched membranes with total protein concentration equal to
0.25 mg/ml (O) and 0.09 mg/ml (N). Thus, the highest concentration
of the active enzyme in our assay can not be more than 1 to 2 nM.
(DOC)
Figure S3 Analysis of different Ab/total AICD ratios
from the published studies [37]. To our knowledge only one
of the published studies analyzed saturation of c-secretase with its
C99 substrate by measuring Km profiles for its different products
[37]. Here we show that the data from Kakuda and co-authors
lead to the same conclusion as our data in Fig. 4A. The reported
Km and Vmax values (shown in table) can be used to calculate the
corresponding saturation curves (eqn. 4 in methods [62]), and the
calculated saturation curves can be used to analyze of different
Ab/total AICD ratios. (A–B) Similar to Fig. 4A, the panels show
that increase in the enzyme saturation with its C99 substrate leads
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saturation 40% of initial AICD cleavages will result in Ab 40 as the
final cleavage product (Fig. 10), only about 2% of initial AICD
cleavages will result in Ab 48 as the final cleavage product (Fig 10).
(C–D) Panels show that the decrease in Ab 40 product
predominantly correlates with the increase in Ab 43, and Ab 49
products. Ab 49–46–43–40 are on the same cleavage path
[37,40,48–50], thus the decrease in Ab 40 can be attributed to
the premature release of the nascent Ab 43 and Ab 49 catalytic
intermediates (Fig. 10). To lesser degree, increase in c-secretase
saturation with it C99 substrate leads to increase in Ab 42, Ab 45
and Ab 48. Ab 48–45–42 are on a different cleavage path than Ab
40 [37,40,48–50]). Thus, to a lesser degree, saturation with C99
substrate can affect the initial c-secretase-C99 complex so that the
initial cleavage takes place at the Ab 48 site rater than the Ab 49
site (Fig. 10). In sum, the data from Kakuda and co-authors [37]
show that increase in the enzyme saturation with its C99 substrate
leads to increase in Ab42/Ab 40 ratio as a result of decrease in Ab
40 and increase in production of the longer more hydrophobic Ab
products.
(DOC)
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